Archives

PRESENTATION TITLE: Nous-209 genetic vaccine encoding shared cancer neoantigens has demonstrated safety and robust immunogenicity in patients with Microsatellite Instable Tumors and is under [...]

PRESENTATION TITLE: Viral Vectors Based Cancer Vaccines For Potent And Effective Anti-Tumour T Cell Immunity. Please find the full report below:

PRESENTATION TITLE: Viral Vectored Vaccines Targeting Tumor Neoantigens elicit potent and effective anti‐tumor immune response. Please find the full report below:

Lynch Syndrome is a common hereditary condition associated with a genetic predisposition to and high-risk of developing colorectal and other cancers Phase 1b trial evaluating NOUS-209 monotherapy [...]

TITLE: Optimized Poxviral promoters improve anti-tumor activity of Modified vaccinia virus Ankara expressing IL12 in mice. Poster P529 Cotugno et al

PRESENTATION TITLE: Rapid generation of clinical grade personalized viral vectored vaccines encoding neoantigens for cancer immunotherapy.

PRESENTATION TITLE: Assessing Immunogenicity & Clinical Activity of Neoantigen Vaccine to Design Successful Vaccines. Please find the full report below:

TITLE: Directed evolution of Adenoviruses to improve vectored vaccines properties.

TITLE: Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL12 for effective antitumor activity Secli’ et al CICON 2023 Please find the full report below:

PRESENTATION TITLE: Personalised Vaccine Construction In Clinical Trial For Cancer Treatment. Please find the full report below: